Table 4. Multivariate linear-mixed model analyses of factors associated with CD8+ T cell counts, CD8% and CD4:CD8 ratio.
| CD8/mm3 | CD8% | CD4 :CD8 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Coef | IC | p | Coef | IC | p | Coef | IC | p | |
| Time from D0 (months) | -3.05 | [-4.05 ; -2.05] | <10−3 | -0.38 | [-0.42;- 0.33] | <0.001 | 0.017 | [0.014 ; 0.019] | <10−3 |
| Sex (female vs male) | -66.3 | [-140.63 ; 8] | 0.08 | -3.49 | [-6.54; -0.45] | 0.025 | 0.13 | [0.05 ; 0.2] | <10−3 |
| Age | 2.34 | [-.68 ; 5.37] | 0.13 | 0.18 | [0.07 ; 0.28] | 0.001 | -0.002 | [-0.004 ; 0] | 0.10 |
| Transmission risk group : | |||||||||
| Heterosexual | na | 1 | 1 | ||||||
| Homo/Bisexual | -3.82 | [-6.66 ; -0.98] | 0.008 | 0.08 | [0.01 ; 0.11] | 0.03 | |||
| Intravenous drug use | -4.16 | [-10.82 ; 2.5] | 0.220 | 0.037 | [-0.12 ; 0.19] | 0.64 | |||
| Other / Unknown | -1.97 | [-5.94 ; 2.01] | 0.331 | -0.033 | [-0.12 ; 0.06] | 0.50 | |||
| HIV follow-up (yrs) | 13.7 | [6.3 ; 21.1] | <10−3 | 0.418 | [0.15 ; 0.69] | 0.003 | -0.009 | [-0.02;-0.002] | 0.01 |
| CDC staging : | na | na | |||||||
| A | 1 | ||||||||
| B | -0.83 | [-4.05 ; 2.38] | 0.611 | ||||||
| C | 2.62 | [-0.78 ; 6.03] | 0.130 | ||||||
| Pre-cART HIV-pVL (Log) | na | -0.36 | [-1.1 ; 0.38] | 0.336 | na | na | na | ||
| Nadir CD4 count (/mm3) | na | -0.03 | [-0.04 ; -0.02] | <0.001 | -0.0093 | [-0.015 ;-0.002] | 0.01 | ||
| CMV+ serology | 220.2 | [118.5 ; 321.9] | <10−3 | 9.72 | [6.25 ; 13.18] | <0.001 | -0.006 | [-0.009 ; -0.004] | <10−3 |
| CMV+ serology *Time from D0 (months) | -0.94 | [-4,2 ; 2,3] | 0.57 | -0.018 | [-0.16 ; 0.12] | 0.8 | -0.006 | [-0.009 ; -0.004] | <10−3 |